Abraham C.F. Leung

1.3k total citations · 1 hit paper
17 papers, 969 citations indexed

About

Abraham C.F. Leung is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Abraham C.F. Leung has authored 17 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Abraham C.F. Leung's work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (5 papers) and HER2/EGFR in Cancer Research (4 papers). Abraham C.F. Leung is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (5 papers) and HER2/EGFR in Cancer Research (4 papers). Abraham C.F. Leung collaborates with scholars based in United States, Spain and South Korea. Abraham C.F. Leung's co-authors include Ian E. Krop, Ron Yu, Antonio González-Martı́n, Hans Wildiers, Sung‐Bae Kim, Melanie C. Smitt, Patricia LoRusso, Jean-Marc Ferrero, Robert S. Janssen and Joseph J. Drabick and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Abraham C.F. Leung

17 papers receiving 944 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

2014 512 citations Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Abraham C.F. Leung

Since Specialization

Citations

This map shows the geographic impact of Abraham C.F. Leung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham C.F. Leung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham C.F. Leung more than expected).

Fields of papers citing papers by Abraham C.F. Leung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham C.F. Leung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham C.F. Leung. The network helps show where Abraham C.F. Leung may publish in the future.

Co-authorship network of co-authors of Abraham C.F. Leung

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham C.F. Leung. A scholar is included among the top collaborators of Abraham C.F. Leung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham C.F. Leung. Abraham C.F. Leung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study 2023 ·Molecular Cancer Therapeutics ·Funda Meric‐Bernstam, Emiliano Calvo, Keun Seok Lee, Víctor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Li Zhou, Steven Pirie‐Shepherd, Abraham C.F. Leung, Giuseppe Curigliano	18
2	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors. 2020 ·Journal of Clinical Oncology ·Funda Meric‐Bernstam, Emiliano Calvo, Víctor Moreno, Hyun Cheol Chung, Yeon Hee Park, Yung‐Jue Bang, Lee S. Rosen, Monica Mita, Ignacio Garrido‐Laguna, Abraham C.F. Leung, (unknown), (unknown), (unknown), (unknown), Giuseppe Curigliano	32
3	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 2019 ·Blood ·Noopur Raje, Andrzej Jakubowiak, Cristina Gasparetto, Robert F. Cornell, Heike I. Krupka, Daniel Navarro, Alison Forgie, Chandrasekhar Udata, Cynthia Basu, Jeffrey Chou, Abraham C.F. Leung, Alexander M. Lesokhin	34
4	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study 2018 ·Cancer Discovery ·Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah Jean Lee Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen	237
5	Abstract CT139: Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study 2018 ·Cancer Research ·Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, (unknown), Emmett V. Schmidt, Abraham C.F. Leung, Robert S. Janssen	1
6	Abstract CT098: Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) 2018 ·Cancer Research ·Ezra E.W. Cohen, (unknown), Douglas Laux, Deborah Jean Lee Wong, Asim Amin, Lisle M. Nabell, Emmett V. Schmidt, Biao Xing, Abraham C.F. Leung, Robert S. Janssen	6
7	Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. 2018 ·Journal of Clinical Oncology ·Antoni Ribas, Mohammed Milhem, Christopher Hoimes, Asim Amin, Inderjit Mehmi, Christopher D. Lao, Robert M. Conry, Montaser Shaheen, Sekwon Jang, April K.S. Salama, Sanjeev Deva, Theresa Medina, Emmett V. Schmidt, Abraham C.F. Leung, Biao Xing, Robert S. Janssen, Georgina V. Long	6
8	Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients. 2017 ·Journal of Clinical Oncology ·Abraham C.F. Leung, Shivaani Kummar, Sanjiv S. Agarwala, John Nemunaitis, René González, Joseph J. Drabick, Emmett V. Schmidt, Elliot Chartash, Biao Xing, Graeme Currie, Robert S. Janssen, Antoni Ribas	6
9	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial 2016 ·Blood ·Ronald Levy, Patrick M. Reagan, Jonathan W. Friedberg, Nancy L. Bartlett, Leo I. Gordon, Abraham C.F. Leung, Joanna Peterkin, Biao Xing, Robert L. Coffman, Robert S. Janssen, Albert F. Candia, Michael S. Khodadoust, Matthew J. Frank, Steven Long, Debra K. Czerwinski, Michael P. Chu	15
10	P08.63 Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients with recurrent glioblastoma 2016 ·Neuro-Oncology ·Andreas F. Hottinger, Marc Sanson, (unknown), Jean‐Pierre Delord, Keyvan Rezaï, Abraham C.F. Leung, (unknown), (unknown), (unknown), Olivier Chinot	3
11	Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB). 2016 ·Journal of Clinical Oncology ·Andreas F. Hottinger, Marc Sanson, (unknown), Jean‐Pierre Delord, (unknown), Keyvan Rezaï, Abraham C.F. Leung, (unknown), Mohamed Békradda, (unknown), François Lokiec, Olivier Chinot	16
12	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial breakdown → 2014 ·The Lancet Oncology ·Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-Marc Ferrero, Melanie C. Smitt, Ron Yu, Abraham C.F. Leung, Hans Wildiers	512
13	Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib. 2014 ·Journal of Clinical Oncology ·Sung‐Bae Kim, Hans Wildiers, Ian E. Krop, Abraham C.F. Leung, (unknown), Ron Yu, Sanne de Haas, Antonio González-Martı́n	4
14	Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer. 2014 ·Journal of Clinical Oncology ·Karen Bartley, Hans Wildiers, Sung‐Bae Kim, Ian E. Krop, Jennifer Kang, Ron Yu, Abraham C.F. Leung, (unknown), Antonio González-Martı́n	3
15	Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer 2013 ·Journal of Clinical Oncology ·Ignace Vergote, Agustin A. García, John P. Micha, Charles H. Pippitt, Johanna C. Bendell, Daniel L. Spitz, Nicholas Reed, G. Dark, Paula M. Fracasso, Emad Ibrahim, Vincent Armenio, Linda Duska, Chris D. Poole, Christine Gennigens, Luc Dirix, Abraham C.F. Leung, Carol Zhao, Raoudha Soufi‐Mahjoubi, Gordon Rustin	34
16	Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. 2011 ·Journal of Clinical Oncology ·(unknown), Ahmad Awada, (unknown), Guy Jérusalem, Rob Coleman, Manon Huizing, (unknown), S.M. O'Reilly, (unknown), Peter Barrett‐Lee, V. Cocquyt, Kostandinos Sideras, (unknown), Martha E. Brown, (unknown), (unknown), Abraham C.F. Leung, (unknown), EA Perez	2
17	Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. 1999 ·PubMed ·William J. Berg, David M. Nanus, Abraham C.F. Leung, Karen T. Brown, Brian Hutchinson, Madhu Mazumdar, Xiao Xu, Reuben Lotan, Victor E. Reuter, Robert J. Motzer	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact